FLUDEOXYGLUCOSE F 18 INJECTION, USP
For Intravenous Use
INDICATIONS AND USAGE
Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:
Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
IMPORTANT SAFETY INFORMATION
Radiation Risk: Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
Blood Glucose Levels: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to administration.
Hypersensitivity reactions with pruritis, edema and rash have occurred; have emergency resuscitation equipment and personnel immediately available.
Click here to view the full prescribing information for Fludeoxyglucose F 18 Injection
PETNET Solutions, 810 Innovation Drive, Knoxville, Tennessee, USA